Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals

Molecular Imaging

Volumn 4, Issue 3, 2005, Pages 182-193

  Harada, Hiroshi ^a   Kizaka Kondoh, Shinae ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Hypoxia response element (HRE); Hypoxia inciucible factor 1 (HIF 1); Luciferase bioluminescence; Optical imaging; Tumor hypoxia

Indexed keywords

BIOMARKERS; CELLS; GENES; GENETIC ENGINEERING; GRAFTS; TUMORS;

HYPOXIA RESPONSE ELEMENT (HRE); LUCIFERASE BIOLUMINESCENCE; OPTICAL IMAGING; TUMOR HYPOXIA;

MEDICAL IMAGING;

HYBRID PROTEIN; PRIMER DNA; TOP3 FUSION PROTEIN;

ANIMAL; ARTICLE; CELL HYPOXIA; HUMAN; IMMUNOHISTOCHEMISTRY; NEOPLASM; NUCLEOTIDE SEQUENCE; OPTICS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; OPTICS; RECOMBINANT FUSION PROTEINS;

EID: 27244433455     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1162/15353500200505112     Document Type: Article

References (41)

1. Vaupel P, Kallinowski F, Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 49:6449-6465.
2. Brown JM (2000). Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today. 6:157-162.
3. Teicher BA (1994). Hypoxia and drug resistance. Cancer Metastasis Rev. 13:139-168.
4. Hockel M, Vaupel P (2001). Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266-276.
5. Harris AL (2002). Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38-47.
6. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509-4515.
7. Giaccia AJ (1996). Hypoxic stress proteins: Survival of the fittest. Semin Radiat Oncol. 6:46-58.
8. O'Rourke JF, Dachs GU, Gleadle JM, Maxwell PH, Pugh CW, Stratford IJ, Wood SM, Ratcliffe PJ (1997). Hypoxia response elements. Oncol Res. 9:327-332.
9. 2 tension. Proc Natl Acad Sci USA. 92: 5510-5514.
10. Bruick RK, McKnight SL (2001). A conserved family of prolyl-4- hydroxylases that modify HIF. Science. 294:1337-1340.
11. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:43-54.
12. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000). Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 275:25733-25741.
13. Ohh M, Park CW, Ivan M, Huffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000). Ubiquitination of hypoxiainducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2:423-427.
14. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000). Activation of HIFlalpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA. 97:10430-10435.
15. Tanimoto K, Makino Y, Pereira T, Poellinger L (2000). Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19: 4298-4309.
16. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721-732.
17. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF (2002). New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther. 13:1737-1750.
18. Kaliberov SA, Buchsbaum DJ, Gillespie GY, Curiel DT, Arafat WO, Carpenter M, Stackhouse MA (2002). Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther. 6: 190-198.
19. Shibata T, Giaccia AJ, Brown JM (2000). Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7:493-498.
20. Vordermark D, Shibata T, Brown JM (2001). Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia. 3:527-534.
21. Liu J, Qu R, Ogura M, Shibata T, Harada H, Hiraoka M (2005). Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo).
22. Shibata T, Giaccia AJ, Brown JM (2002). Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 4:40-48.
23. Harada H, Hiraoka M, Kizaka-Kondoh S (2002). Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 62:2013-2018.
24. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M (2003). Tumor hypoxia: A target for selective cancer therapy. Cancer Sci. 94: 1021-1028.
25. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science. 285:1569-1572.
26. Wadia JS, Dowdy SF (2005). Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev. 57:579-596.
27. Inoue M, Mukai M, Hamanaka Y, Tatsuta M, Hiraoka M, KizakaKondoh S (2004). Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol. 25:713-720.
28. Kim DW, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S (1990). Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene. 91:217-223.
29. Sunohara T, Jojima K, Tagami H, Inada T, Aiba H (2004). Ribosome stalling during translation elongation induces cleavage of mRNA being translated in Escherichia coli. J Biol Chem. 279:15368-15375.
30. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH. (1999). Visualizing the kinetics of tumorcell clearance in living animals. Proc Natl Acad Sci USA. 96:12044-12049.
31. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr., Raleigh JA (1998). Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 71: 270-277.
32. Chen WT, Tung CH, Weissleder R (2004). Imaging reactive oxygen species in arthritis. Mol Imaging. 3:159-162.
33. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D (2003). Imaging 26S proteasome activity and inhibition in living mice. Nat Med. 9:969-973.
34. Ray P, Pimenta H, Paulmurugan R, Berger F, Phelps ME, Iyer M, Gambhir SS (2002). Noninvasive quantitative imaging of protein-protein interactions in living subjects. Proc Natl Acad Sci USA 99:3105-3110.
35. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, Ageyeva L, Serganov A, Cai S, Balatoni J, Blasberg R, Gelovani J (2004). Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res. 64: 6101-6108.
36. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU (2004). Differentiating the functional role of hypoxia-inducible factor (HIF)-lalpha and HIF-2alpha (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 18:1462-1464.
37. Vaupel P (2004). The role of hypoxia-induced factors in tumor progression. Oncologist. 5:10-17.
38. Raleigh JA, Koch CJ (1990). Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biocbem Pharmacol. 40:2457-2464.
39. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000). Modulation of hypoxia-inducible factor lalpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541-1545.
40. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000). Up-regulation of hypoxia-inducible factors HIF-lalpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 19:5435-5443.
41. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S (2003). Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell. 113:717-730.